---
title: "廣州銀諾醫藥集團股份有限公司 (02591.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/02591.HK.md"
symbol: "02591.HK"
name: "廣州銀諾醫藥集團股份有限公司"
industry: "生物技術"
---

# 廣州銀諾醫藥集團股份有限公司 (02591.HK)

| Item | Detail |
|------|--------|
| Industry | 生物技術 |
| Location | 港股市場 |
| Website | [www.innogenpharm.com](https://www.innogenpharm.com) |

## Company Profile

廣州銀諾醫藥集團股份有限公司是一家主要從事醫藥產品的研發及商業化的中國投資控股公司。該公司主要從事商業化原研人源長效胰高血糖素樣肽-1(GLP-1)受體激動劑。該公司致力於開發糖尿病和其他代謝性疾病的療法。該公司的主要產品依蘇帕格魯肽α(商品名:怡諾輕)用於治療2型糖尿病(T2D)。該公司的主要候選藥物管線產品包括YN014、YN401、YN209、YN203和YN202。該公司主要在國內市場經營其業務。

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -51.82 | 57/70 | - | - | - |
| PB | 16.84 | 49/70 | 25.69 | 20.26 | 18.70 |
| PS (TTM) | 101.85 | 51/70 | 155.36 | 122.52 | 113.07 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-11T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 27.60 |
| Highest Target | 34.54 |
| Lowest Target | 34.54 |

## References

- [Company Overview](https://longbridge.com/en/quote/02591.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/02591.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/02591.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.